OCUGEN INC. - COMMON STOCK

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

05 Mar 2025 07:02:00 By Nasdaq GlobeNewswire

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

03 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

27 Feb 2025 08:46:50 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

21 Feb 2025 08:00:45 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

12 Feb 2025 07:42:23 By Nasdaq GlobeNewswire

Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

03 Feb 2025 06:30:42 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

27 Jan 2025 06:30:20 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

16 Jan 2025 07:30:38 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

13 Jan 2025 06:30:46 By Nasdaq GlobeNewswire

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

19 Dec 2024 06:38:37 By Nasdaq GlobeNewswire

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

11 Dec 2024 07:02:18 By Nasdaq GlobeNewswire

Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference

27 Nov 2024 07:09:58 By Nasdaq GlobeNewswire

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

20 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

19 Nov 2024 07:02:34 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

08 Nov 2024 06:45:51 By Nasdaq GlobeNewswire

Ocugen Secures $30 Million in Debt Funding

07 Nov 2024 06:30:55 By Nasdaq GlobeNewswire

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

28 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

22 Oct 2024 07:02:15 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

17 Oct 2024 07:30:11 By Nasdaq GlobeNewswire

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

10 Oct 2024 07:00:00 By Nasdaq GlobeNewswire